Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Case of Lambda-like ST-elevation in Acute MI
Author(s): Heng Shee Kim , Hou Tee Lu Added: 1 year ago

Electrophysiology & Arrhythmia

MI/ACS
Outcomes of Ticagrelor Following Fibrinolysis: Australian Data
Author(s): Rohullah Sultani , Jasmine Chan , Timothy Abrahams , et al Added: 1 week ago

Anticoagulation

MI/ACS
False STEMI Score for Predicting False STEMI Activation
Author(s): Natnicha Pongbangli , Thanaporn Anuchai , Sasivimon Jai-aue , et al Added: 4 weeks ago

Digital Health

Prevention & Chronic Conditions
OMI Confounded by LVH
Author(s): Bayushi Eka Putra , Ignatius Yansen Ng Added: 2 months ago

Intervention

MI/ACS
Lipoprotein(a) May be Falsely Lowered When Troponin T is Elevated
Author(s): Colin Yeo , Xuan Han Koh , Weien Chow , et al Added: 9 months ago

MI/ACS

Prevention & Chronic Conditions
RV Free Wall Strain and Angiographic Correlation in Acute Inferior STEMI
Author(s): Kapil Rajendran , Abdul Salam , Jayaram Vasu Added: 1 year ago

Imaging & Diagnostics

Intervention
Multisystem Inflammatory Syndrome in an Adult: A Rare Cause of STEMI
Author(s): Billy Joseph David , Reynald Evan R Tugade , Ferdinand Jr Gerodias Added: 2 years ago

Heart Failure

Prevention & Chronic Conditions
ESC 25: LipoaScreen: Cascade Screening for LP(a)
Author(s): Jonas Brinck Added: 5 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 8 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
GLP-1 RAs in T2D and Established or High-risk ASCVD
Author(s): Wanwarang Wongcharoen , Rungroj Krittayaphong , Wacin Buddhari , et al Added: 9 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions